Wockhardt Ltd vs Zydus Lifesciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Wockhardt Ltd is ₹ 1537 as of 05 May 15:30 . The P/E Ratio of Wockhardt Ltd changed from 6.7 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Zydus Lifesciences Ltd changed from 21.1 on March 2021 to 19.7 on March 2025 . This represents a CAGR of -1.36% over 5 years The Market Cap of Wockhardt Ltd changed from ₹ 4590 crore on March 2021 to ₹ 23133 crore on March 2025 . This represents a CAGR of 38.19% over 5 yearsThe Market Cap of Zydus Lifesciences Ltd changed from ₹ 45131 crore on March 2021 to ₹ 89122 crore on March 2025 . This represents a CAGR of 14.58% over 5 years The revenue of Wockhardt Ltd for the Mar '26 is ₹ 1032 crore as compare to the Dec '25 revenue of ₹ 913 crore. This represent the growth of 13.03% The revenue of Zydus Lifesciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 6975 crore. This represent the decline of -100% The ebitda of Wockhardt Ltd for the Mar '26 is ₹ 292 crore as compare to the Dec '25 ebitda of ₹ 192 crore. This represent the growth of 52.08% The ebitda of Zydus Lifesciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 1842 crore. This represent the decline of -100% The net profit of Wockhardt Ltd changed from ₹ -16 crore to ₹ 164 crore over 8 quarters. This represents a CAGR of NaN% The net profit of Zydus Lifesciences Ltd changed from ₹ 1463 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Wockhardt Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Zydus Lifesciences Ltd changed from 24.28 % on March 2021 to 19.16 % on March 2025 . This represents a CAGR of -4.63% over 5 years .

About Wockhardt Ltd

Wockhardt Limited, incorporated in July, 1999 is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world.
The Company is India's leading research-based global healthcare enterprise in fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals.
It has 12 manufacturing locations and there are 3 locations where research and development activities are carried out. The Company has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland.
It has a significant presence in USA, Europe and India, with 83% of its global revenues coming from international businesses.
Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified lnfectious Diseases Programme) for 5 of Anti-bacterial discovery programmes - 2 of them are Gram Negative and 3 Gram Positive effective against untreatable 'Superbugs'.

About Zydus Lifesciences Ltd

Zydus Lifesciences Limited, initially known as Cadila Healthcare Limited was incorporated in May, 1995, which changed to Zydus Lifesciences Limited on February 24, 2022.
The Company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products.
The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. The Company's operation includes pharmaceuticals, which includes human formulations, veterinary formulations and bulk durgs, diagnostics, herbal products, skin care products and OTC products.

FAQs for the comparison of Wockhardt Ltd and Zydus Lifesciences Ltd

Which company has a larger market capitalization, Wockhardt Ltd or Zydus Lifesciences Ltd?

Market cap of Wockhardt Ltd is 24,979 Cr while Market cap of Zydus Lifesciences Ltd is 91,753 Cr

What are the key factors driving the stock performance of Wockhardt Ltd and Zydus Lifesciences Ltd?

The stock performance of Wockhardt Ltd and Zydus Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Wockhardt Ltd and Zydus Lifesciences Ltd?

As of May 5, 2026, the Wockhardt Ltd stock price is INR ₹1537.25. On the other hand, Zydus Lifesciences Ltd stock price is INR ₹911.85.

How do dividend payouts of Wockhardt Ltd and Zydus Lifesciences Ltd compare?

To compare the dividend payouts of Wockhardt Ltd and Zydus Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.